CyberKnife Radiosurgery

Introduction

If your doctor has recommended CyberKnife radiosurgery, you are probably trying to understand what it actually involves, whether it is right for your kind of tumour, and what life looks like during and after treatment. The word “radiosurgery” can sound intimidating, but CyberKnife is not surgery in the traditional sense. There are no incisions, no general anaesthesia, and usually no hospital stay.

CyberKnife is a robotic system that delivers very precisely focused radiation to a tumour over a small number of sessions. It is one of several technologies used in modern radiation oncology to deliver what is called stereotactic radiosurgery (SRS) for tumours in the head, and stereotactic body radiation therapy (SBRT) for tumours elsewhere in the body. This article walks through what CyberKnife is, who it is generally used for, how the planning and treatment unfold, what side effects to expect, and how it compares with other options. The right treatment in any individual case is a decision made by you with your radiation oncologist and the wider cancer team.

What Is CyberKnife Radiosurgery?

CyberKnife is a brand name for a robotic radiation delivery system that performs stereotactic radiosurgery and stereotactic body radiation therapy. In plain terms, it is a small linear accelerator (the machine that produces radiation beams) mounted on a robotic arm that can move around you and aim beams from many different angles. Imaging cameras built into the system continuously check the position of your tumour and adjust the beam during treatment.

The goal is to deliver a high dose of radiation to the tumour while keeping the dose to surrounding healthy tissue as low as possible. Because the dose per session is high and the targeting is very precise, treatment can be completed in a small number of sessions — typically one to five — compared with the 20 to 40 sessions used in conventional radiation therapy.

Important Terms Explained

• Stereotactic radiosurgery (SRS): Highly focused radiation delivered to a target in the brain or spine, usually in one to five sessions. It is called “radiosurgery” because the effect is surgery-like in precision, not because cutting is involved.
• Stereotactic body radiation therapy (SBRT): The same concept applied to tumours outside the brain — for example, in the lung, liver, prostate, or pancreas.
• Gray (Gy): The unit used to measure radiation dose.
• Fractionation: Dividing a total radiation dose into smaller sessions. CyberKnife uses fewer, larger fractions (called hypofractionation) rather than many small ones.
• Linear accelerator (linac): The machine that produces the radiation beams.

CyberKnife is one of several stereotactic platforms. Others include Gamma Knife (used mainly for brain targets, with a fixed head frame), and linear-accelerator-based SBRT systems used in many cancer centres. The underlying principle — precise, high-dose, image-guided radiation — is shared across these platforms.

Why Is CyberKnife Radiosurgery Performed?

CyberKnife is used to treat both cancerous (malignant) and non-cancerous (benign) tumours, and certain non-tumour conditions such as abnormal blood vessel formations. Whether it is the right option depends on the type, size, number, and location of the tumour, and on your overall health and previous treatments. Major radiation oncology societies, including ASTRO and groups such as the NCCN, include stereotactic radiation as a recognised option for several specific situations described below.

Brain and Central Nervous System

• Brain metastases (cancer that has spread to the brain from another site)
• Selected primary brain tumours
• Acoustic neuroma (vestibular schwannoma) and other benign skull-base tumours
• Meningiomas
• Arteriovenous malformations (AVMs) — abnormal tangles of blood vessels
• Trigeminal neuralgia in some patients

Spine

• Spinal metastases, particularly when pain control or local tumour control is needed
• Selected primary spinal tumours

Lung

• Early-stage non-small cell lung cancer in patients who are not surgical candidates, or who choose not to have surgery
• Selected lung metastases (oligometastatic disease)

Prostate

• Localised prostate cancer, where SBRT is an established radiation option alongside conventional external beam radiotherapy and brachytherapy

Liver and Pancreas

• Primary liver cancers (such as hepatocellular carcinoma) and liver metastases that cannot be removed surgically
• Locally advanced pancreatic cancer in selected cases, usually as part of a wider treatment plan

Other Sites

• Selected kidney, adrenal, and lymph node metastases
• Re-irradiation of a recurrent tumour in an area that has previously received radiation, when conventional re-treatment would be too risky

Doctors typically consider CyberKnife or other stereotactic radiation when surgery is high risk, when the tumour is in a hard-to-reach location, when a patient prefers a non-invasive approach, or when a small number of metastases need focused control. The final choice is made after multidisciplinary discussion that includes surgeons, medical oncologists, and radiation oncologists.

Who Is a Candidate?

Not every tumour is suitable for stereotactic radiation. CyberKnife generally works best when:

• The tumour is relatively small and well-defined on imaging
• The number of targets is limited (for example, a few brain metastases rather than widespread disease)
• The tumour is in a location where high-dose radiation can be safely focused without damaging critical nearby structures
• You are well enough to lie still on a treatment table for 30 to 90 minutes

CyberKnife may be less suitable when:

• The tumour is very large, in which case conventional fractionated radiation may give better dose distribution
• Disease is widespread, where systemic therapy (chemotherapy, immunotherapy, or targeted therapy) is the priority
• Surgery offers a clearly better outcome and the patient is fit for it
• The tumour sits immediately adjacent to a very radiation-sensitive structure that cannot tolerate even a small high-dose region

Your suitability is decided by the radiation oncology team after reviewing your imaging, pathology reports, prior treatments, and overall health.

Alternatives to CyberKnife

CyberKnife is one of several options, and understanding the alternatives helps you have a more informed conversation with your team.

Surgery

For many tumours — including early-stage lung cancer, some brain tumours, and localised prostate cancer — surgery is an established option and may be preferred when the patient is fit and the tumour is accessible. Surgery removes the tumour physically and provides tissue for detailed pathology.

Conventional External Beam Radiation Therapy

Standard radiotherapy delivers smaller doses over many sessions (commonly 20 to 40). It is often used when the tumour is large, when a wider area needs treatment, or when dose limits around the tumour rule out a stereotactic approach. Intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) are common modern forms.

Other Stereotactic Platforms

• Gamma Knife: A stereotactic system used mainly for brain targets, traditionally with a rigid head frame, though frameless versions exist.
• Linac-based SBRT/SRS: Many cancer centres deliver stereotactic radiation using a conventional linear accelerator with specialised planning and imaging. Clinical outcomes for many indications are broadly similar across well-run platforms.
• Proton beam therapy: Uses protons rather than X-rays; sometimes considered for paediatric tumours or for tumours close to very sensitive structures, where it is available.

Systemic Therapy

Chemotherapy, targeted therapy, immunotherapy, and hormone therapy treat cancer throughout the body. For widespread or systemically driven disease, these are usually central, and radiation (including CyberKnife) is used alongside them for specific tumour sites.

Active Surveillance

For some slow-growing tumours — certain small acoustic neuromas, meningiomas, or low-risk prostate cancers — close monitoring with imaging or blood tests, without immediate treatment, is a valid option that may be discussed.

Preparing for CyberKnife Treatment

Treatment is carefully planned before any radiation is delivered. The planning phase usually takes one to two weeks.

Consultation and Review

The radiation oncologist reviews your diagnosis, imaging, pathology, and prior treatments. You will discuss what CyberKnife can and cannot achieve in your case, the likely number of sessions, expected side effects, and alternatives. This is the right time to ask questions and to bring a family member if that helps.

Simulation Scan

Immobilisation

To keep you steady during treatment:

• For brain or head-and-neck targets, a custom thermoplastic mask is moulded to your face. It is snug but not painful.
• For body sites, a vacuum cushion or body cradle may be made.
• Unlike Gamma Knife, CyberKnife does not require pins or a rigid head frame.

Fiducial Markers (When Needed)

For some tumours that move with breathing or that are hard to see on imaging — commonly in the prostate, liver, lung, or pancreas — small inert metal markers called fiducials may be placed in or near the tumour by a short procedure beforehand. These act as reference points for the tracking system.

Plan Design

Medical physicists and the radiation oncologist work together to design a plan that:

• Delivers the prescribed dose to the tumour
• Spreads entry points across many angles to limit dose to any single area of healthy tissue
• Keeps the dose to critical organs (such as the spinal cord, optic nerves, bowel, or bladder) below safe thresholds

Quality checks are run on the plan before your first session.

Practical Preparation

• You can usually eat normally before treatment unless your team gives specific instructions (for example, a comfortably full or empty bladder for some prostate or pelvic treatments).
• Wear comfortable, loose clothing.
• Continue most medications unless told otherwise. Tell your team about all medicines and supplements you take.
• Arrange transport if you feel anxious about driving immediately afterwards, though most people can drive themselves home.

What Happens During CyberKnife Treatment

The session itself is straightforward and painless. Many patients are surprised at how undramatic it feels.

• You lie on the treatment couch in the same position as during your planning scan.
• Your mask or cushion is positioned to keep you still.
• The robotic arm moves slowly around you, pausing at different angles to deliver short bursts of radiation.
• Imaging cameras take pictures of your tumour or fiducials throughout the session. If you shift slightly or breathe, the system adjusts the beam to compensate.
• You will not see, feel, or smell the radiation. You may hear soft mechanical sounds from the robotic arm and imaging systems.
• Staff watch you on cameras from the next room and can speak with you through an intercom at any time.

Each session typically lasts 30 to 90 minutes, depending on the site and the complexity of the plan. Sessions are usually given on consecutive days or every other day, completing the whole course within about a week.

General anaesthesia is not used for adults. Light sedation may occasionally be considered for patients who cannot tolerate lying still, and is more often a consideration in children (see the paediatric section below).

Recovery and Healing

Because there are no incisions, recovery in the usual surgical sense does not apply. Most patients go home the same day and return to light activities within 24 to 48 hours. Specific timelines depend on the treated site.

The First Few Days

• Mild fatigue is the most common immediate effect.
• Localised skin redness may appear over the treated area; this is usually mild with stereotactic radiation because beam entry is spread over many angles.
• Pain at the tumour site is uncommon but possible, and is usually controlled with simple painkillers.
• You can typically eat normally, sleep in your usual position, and bathe normally.

The First Few Weeks

• Fatigue may persist for a couple of weeks and then gradually improve.
• Site-specific effects (described below) may appear and settle over this period.
• Most people return to work, exercise, and travel within a week or two, depending on the site and on how they feel.

Tumour Response

Radiation works by damaging the DNA of tumour cells so that they can no longer divide. Tumours often shrink slowly over weeks to many months after treatment, rather than disappearing immediately. Some tumours stabilise rather than visibly shrink, which can still represent successful local control. This is normal and is followed with scheduled imaging.

Follow-up

A typical follow-up plan includes:

• A first review a few weeks after treatment to check on symptoms and side effects.
• Imaging (MRI, CT, or PET, depending on the site) at intervals over the first year and then less frequently afterwards.
• Blood tests where appropriate (for example, PSA after prostate treatment).
• Ongoing care with your wider cancer team, including any systemic therapy that may continue alongside or after radiation.

Side Effects and Risks

Side effects depend on which part of the body is treated, the dose given, and your overall health. Because CyberKnife concentrates the dose on the tumour, side effects are often more localised and milder than with conventional radiation, but they are not zero.

General Side Effects

• Fatigue, often the most reported symptom
• Mild skin changes over the treated area
• Localised swelling or inflammation around the tumour
• Temporary nausea, particularly if the brain or upper abdomen is treated

Site-Specific Effects

• Brain: Headaches, mild nausea, temporary worsening of nearby neurological symptoms due to swelling. Steroids are sometimes prescribed to manage swelling. Rarely, radiation necrosis — an area of damaged tissue at the treated site — develops months later and may need specific treatment.
• Spine: Temporary increase in back pain (a “pain flare”) in the first days after treatment; usually managed with short courses of steroids or painkillers. Rarely, compression fractures of the treated vertebra over time.
• Lung: Cough, mild breathlessness, and rarely radiation pneumonitis (inflammation of the lung) weeks after treatment.
• Prostate: Urinary frequency, urgency, or mild bowel irritation. Sexual function can be affected over time, similar to other forms of prostate radiation.
• Liver and pancreas: Nausea, fatigue, mild abdominal discomfort, and in some cases temporary changes in liver function tests.
• Head and neck: Dry mouth, taste changes, or skin reactions, depending on the precise target.

Less Common but More Serious Risks

• Damage to a critical nearby structure (for example, an optic nerve, the spinal cord, or bowel), which is why planning carefully avoids dose to these organs.
• Bleeding from a tumour after treatment, particularly in certain lung or liver tumours.
• Second cancers caused by radiation many years later — a small but recognised long-term risk of any radiation, more relevant in younger patients.

Your radiation oncologist will discuss the risks specific to your situation. Report new or worsening symptoms early so they can be assessed and managed.

Outcomes and Effectiveness

Effectiveness is usually described in terms of local control — how often the treated tumour stops growing or shrinks — rather than cure of the whole cancer, especially when CyberKnife is part of a wider plan. Outcomes depend strongly on tumour type, size, location, biology, and stage.

Broad qualitative patterns from the radiation oncology literature include:

• For early-stage non-small cell lung cancer in patients who cannot have surgery, SBRT achieves high rates of local tumour control comparable to surgery in selected patients.
• For a limited number of brain metastases, stereotactic radiosurgery is an established alternative or addition to whole-brain radiation, and is often favoured for cognitive preservation.
• For localised prostate cancer in suitable patients, SBRT produces long-term disease control similar to conventional radiation schedules, with a shorter overall treatment time.
• For spinal metastases, SBRT often gives durable pain relief and local control.
• For benign tumours such as acoustic neuromas and small meningiomas, stereotactic radiosurgery commonly halts growth in a high proportion of cases.

Specific numbers for your situation are best discussed with your radiation oncologist, who can take into account your tumour type, imaging, and overall plan.

Life After CyberKnife Treatment

Once the course is complete, most people return to their normal routine quickly, while continuing under the care of the cancer team. A few practical points often come up.

Daily Life

• Work, driving, exercise, and travel are generally fine within days to a couple of weeks for most patients, depending on the site treated.
• You are not radioactive after external beam treatment, including CyberKnife. It is safe to be around children, pregnant women, and pets.
• Sun protection on any treated skin area is sensible, particularly in the first months.

Ongoing Cancer Care

For many patients, CyberKnife is one step in a longer cancer journey that may include surgery, systemic therapy, hormone therapy, or further radiation. Coordinated care across specialists is essential, and your radiation oncologist will share your treatment summary with your other doctors.

Emotional Wellbeing

Finishing active treatment can bring a mix of relief, anxiety about recurrence, and fatigue. Counselling, support groups, and open conversations with your care team are helpful for many patients and families.

CyberKnife in Children

Children may need stereotactic radiation for selected brain tumours, arteriovenous malformations, or other carefully chosen targets. However, paediatric radiation is approached differently from adult radiation because:

• Young, growing tissues are more sensitive to radiation, including the risk of long-term effects on growth, hormone function, learning, and the small but real risk of a second cancer decades later.
• Lying still for a long session is harder for children, so light sedation or general anaesthesia is sometimes needed.
• Proton beam therapy, where available, is often considered first for certain paediatric tumours because it can reduce dose to surrounding developing tissues.

Paediatric cases are managed by teams that include paediatric oncologists, radiation oncologists with paediatric experience, and anaesthetists. The decision to use CyberKnife versus other radiation platforms or non-radiation approaches is made on a case-by-case basis after detailed discussion with the family.

Frequently Asked Questions

Is CyberKnife actually surgery?

No. There are no incisions and no cutting. The term “radiosurgery” refers to the surgery-like precision of the radiation, not to any physical cutting.

Does CyberKnife hurt?

The treatment itself is painless. You may feel mild discomfort from lying still or wearing a mask, but the radiation itself cannot be felt.

How many sessions will I need?

Most patients receive between one and five sessions, usually within a single week. The exact number depends on the tumour type, size, and location, and is decided by your radiation oncologist.

Will I lose my hair?

Hair loss only happens in the area where radiation beams pass through the scalp. For brain tumour treatments, some patchy hair thinning over the treated region is possible and often temporary. Whole-head hair loss does not occur.

Will I be radioactive?

No. External beam treatments such as CyberKnife do not make you radioactive. You can safely be around family members, including children and pregnant women, immediately after each session.

How is CyberKnife different from Gamma Knife?

Both are stereotactic radiosurgery systems. Gamma Knife uses cobalt-60 sources arranged in a fixed helmet and is used almost exclusively for brain and upper-spine targets, often with a head frame. CyberKnife uses a small linear accelerator on a robotic arm and can treat targets throughout the body, without a rigid head frame. For many brain conditions, outcomes between the two are broadly similar; the choice often depends on availability and local expertise.

How is CyberKnife different from conventional radiation?

Conventional radiation typically delivers smaller doses across many sessions over several weeks. CyberKnife delivers larger, more focused doses in one to five sessions. For specific tumour types and sizes, stereotactic radiation has become a standard option; for others, conventional fractionated radiation remains preferred.

Can CyberKnife treat tumours that have already been irradiated?

In some carefully selected cases, yes. Re-irradiation with stereotactic techniques is an active area of practice when a tumour recurs in or near a previously treated area, but it requires careful planning and a frank discussion of risks.

How soon will I know if it worked?

Tumour shrinkage usually unfolds over weeks to months. Follow-up imaging is typically done at two to three months and then at intervals afterwards. Some tumours stabilise rather than visibly shrink, which can still represent a successful outcome.

Can I have CyberKnife alongside chemotherapy or immunotherapy?

Often yes, but the timing needs to be coordinated. Your medical oncologist and radiation oncologist will plan the sequence to balance effectiveness and safety.

Conclusion

CyberKnife radiosurgery is a non-invasive, image-guided form of stereotactic radiation that delivers focused, high-dose treatment to tumours in the brain, spine, lung, prostate, liver, and other sites, typically over one to five sessions. For many patients — particularly those with small, well-defined tumours, those who are not surgical candidates, or those who need a precisely targeted approach — it is one of several established options in modern radiation oncology.

Whether CyberKnife is the right choice in any individual case depends on the tumour, the wider treatment plan, and a detailed discussion with the radiation oncology team and the rest of the cancer care team. Understanding what the treatment involves, what to expect afterwards, and where it sits among the alternatives helps you take part in that conversation with greater confidence.